Recent development in carbohydrate-based cancer vaccines.
Recent development in carbohydrate-based cancer vaccines.
复制标题
DOI：
10.1016/j.cbpa.2009.08.010
复制
发表时间：
2009-12
影响因子：
7.8
通讯作者：
Wang, Qianli
中科院分区：
文献类型：
--
作者：
Guo, Zhongwu;Wang, Qianli
肿瘤相关糖类抗原(TACA)是肿瘤细胞表面的重要分子标志物，对肿瘤疫苗或肿瘤免疫治疗的研究具有重要意义。然而，由于其免疫原性和/或免疫耐受性差，大多数TACA不能诱导T细胞介导的免疫，而T细胞介导的免疫是癌症治疗的关键。本文综述了近年来通过构建具有更高免疫原性的TACA结合物来克服这一问题的努力，如通过将TACA共价偶联到适当的载体分子上以形成簇状或多表位结合疫苗，将TACA偶联到T细胞肽表位和/或免疫刺激表位以形成完全合成的多组分糖结合疫苗，以及开发基于化学修饰的TACA的疫苗，并将其与癌细胞代谢工程相结合。
Tumor-associated carbohydrate antigens (TACAs) are important molecular markers on the cancer cell surface, useful for the development of therapeutic cancer vaccines or cancer immunotherapies. However, due to their poor immunogenicity and/or immunotolerance, most TACAs fail to induce T cell-mediated immunity that is critical for cancer therapy. This review summarizes the recent effort to overcome this problem via constructing TACA conjugates with improved immunogenicity, such as by covalently coupling TACAs to proper carrier molecules to form clustered or multi-epitopic conjugate vaccines, coupling TACAs to a T cell peptide epitope and/or an immunostimulant epitope to form fully synthetic multi-component glycoconjugate vaccines, and developing vaccines based on chemically modified TACAs, which is combined with metabolic engineering of cancer cells.
登录
查看更多内容
影响因子：
4.3
作者：
Buskas, T;Li, YH;Boons, GJ
通讯作者：
Boons, GJ
影响因子：
2.9
作者：
Chefalo, P;Pan, YB;Harding, CV
通讯作者：
Harding, CV
影响因子：
5.8
作者：
ADLURI, S;HELLING, F;LIVINGSTON, PO
通讯作者：
LIVINGSTON, PO
影响因子：
4.7
作者：
Grigalevicius, S;Chierici, S;Dumy, P
通讯作者：
Dumy, P
影响因子：
6.2
作者：
Holmberg, Leona A;Sandmaier, Brenda M
通讯作者：
Sandmaier, Brenda M